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Erythropoietin enhances Kupffer 
cell number and activity in the 
challenged liver
Dafna Gilboa1, Yasmin Haim-Ohana1, Naamit Deshet-Unger1, Nathalie Ben-Califa1, Sahar 
Hiram-Bab2, Debby Reuveni3, Ehud Zigmond3, Max Gassmann4, Yankel Gabet2, Chen Varol3 & 
Drorit Neumann1
Erythropoietin (EPO) is the main hormone driving mammalian erythropoiesis, with activity mediated 
via the surface receptor, EPO-R, on erythroid progenitor cells. Recombinant human EPO is currently 
used clinically for the treatment of anemia in patients with end-stage renal disease, and in certain 
cancer patients suffering from anemia induced either by the tumor itself or by chemotherapy. 
EPO-R expression is also detected in non-erythroid cells, including macrophages present in the 
peritoneum, spleen, and bone marrow (BM). Here we demonstrate that Kupffer cells (KCs) - the liver-
resident macrophages - are EPO targets. We show that, in vitro, EPO initiated intracellular signalling 
and enhanced phagocytosis in a rat KC line (RKC-2) and in sorted KCs. Moreover, continuous EPO 
administration in mice, resulted in an increased number of KCs, up-regulation of liver EPO-R expression 
and elevated production of the monocyte chemoattractant CCL2, with corresponding egress of Ly6Chi 
monocytes from the BM. In a model of acute acetaminophen-induced liver injury, EPO administration 
increased the recruitment of Ly6Chi monocytes and neutrophils to the liver. Taken together, our results 
reveal a new role for EPO in stimulating KC proliferation and phagocytosis, and in recruiting Ly6Chi 
monocytes in response to liver injury.
Erythropoietin (EPO) is the main hormone that drives mammalian erythropoiesis in response to hypoxia, 
through activation of the hypoxia inducible factor HIF-21. It is synthesized by the adult kidney and by the 
fetal liver as well as by the adult liver2, 3 and regulates the production of red blood cells via its receptor, EPO-R. 
Recombinant human EPO (rHuEPO) is currently used in clinical applications for the treatment of anemia asso-
ciated with chronic renal failure4, 5, as well as for alleviating chemotherapy or radiotherapy-induced anemia in 
certain cancer patients6. However, it has become clear that the indications that can benefit from EPO treatment 
extend beyond anemia7–15. EPO treatment has been found to have a tissue-protective effect in animal models 
reflecting a wide variety of tissues. Among others, the beneficial effects of EPO have been reported in various 
models of liver injuries such as fibrosis, ischemia/reperfusion (I/R) injury, and extended liver resection16–18. In 
addition, the combination of G-CSF (Granulocyte Colony-Stimulating Factor) and Darbepoetin α, an EPO deriv-
ative with prolonged serum half-life, provided clinical benefit and improved survival in patients with decompen-
sated liver disease19.
The liver is a unique immunological organ and one of the first lines of host defense. Its unique structure and 
diverse cell composition drive the host defense against the dissemination of pathogens through the blood20, 21. 
Kupffer cells (KCs) are the largest population of resident macrophages in the body and their primary function is 
to protect the liver from bacterial infections. Their location within the sinusoidal vascular space, predominantly 
in the periportal area, places these cells in the perfect position to clear gut-derived bacteria, endotoxins, debris, 
and metabolic waste arriving at the liver via the portal vein22, 23. KCs display high phagocytic and lysosomal activ-
ity, which highlights their specialization in monitoring and filtering the blood entering the sinusoids.
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Coupling between EPO driven erythropoiesis, iron metabolism, and clearance of senescent and damaged 
erythrocytes by macrophages, is a key factor in red blood cell homeostasis1. KCs play a crucial role in hepatic 
iron metabolism and erythrocyte turnover24, 25. We and others have shown that macrophages from the spleen, 
peritoneum26 and BM27–29 express functional EPO-Rs and they respond to treatment with EPO. Nevertheless, an 
answer to the question of whether KCs are targets of EPO activity has remained elusive. Here we demonstrate that 
KCs express functional EPO-Rs and that EPO treatment promotes their proliferation and phagocytosis capability. 
Moreover, EPO stimulates KC-mediated attraction of CCR2+Ly6Chi monocytes to the challenged liver via the 
production of their chemoattractant - CCL2.
Results
The RKC-2 Kupffer cell line expresses a functional EPO-R. To address the question of whether KCs 
respond to EPO, we initially utilized the rat Kupffer cell line, RKC-2, as a model system30. We measured the 
expression levels of EPO-R transcripts and protein in RKC-2 cells in the presence or absence of EPO. Bone mar-
row-derived macrophages (BMDM) were referenced as a positive control for EPO-R expression27, 29. RT-PCR 
analysis detected EPO-R mRNA transcripts in these cells (Fig. 1A) and 24 h treatment with EPO led to a 60% 
increase (p < 0.05) in the levels of EPO-R transcripts. Flow cytometry analysis using a recently validated new 
monoclonal antibody directed against EPO-R31, further confirmed its expression at the protein level and a 24 h 
treatment with EPO led to a 34% decrease (p < 0.01) in the levels of cell surface EPO-R (Fig. 1B). These data are in 
accordance with previous reports demonstrating EPO mediated EPO-R endocytosis and internalization in vari-
ous cell types32–34. In response to EPO binding, JAK2 is activated and phosphorylates Tyr residues on the EPO-R, 
which can then recruit and activate ERK1/2 and STAT5 among other secondary signalling molecules35, 36. In this 
regard, flow cytometry analysis demonstrated that EPO induces phosphorylation of ERK1/2 (Fig. 1C) and STAT5 
(Fig. 1D), and that the response peaks at 10 minutes.
EPO up-regulates phagocytosis by KCs. EPO enhances phagocytosis by peritoneal macrophages and 
BMDM via EPO-R27, 29, 37, 38. We thus questioned whether EPO could also increase the phagocytic capacity of 
KCs. We measured the effect of EPO on the ability of RKC-2 cells and sorted primary mouse KCs to phagocytose 
fluorescence-labeled polystyrene microbeads or CFSE (Carboxyfluorescein succinimidyl ester fluorescent cell 
staining dye) - labeled heat killed E. coli. The degree of phagocytosis of fluorescence-labeled polystyrene microbe-
ads was determined by fluorescence microscopy (Fig. 2A) and flow cytometry analysis (Fig. 2B). Pre-treatment 
with EPO increased the capacity of RKC-2 phagocytosis of microbeads by 540% (p < 0.01) and 32% (p < 0.01), 
Figure 1. EPO regulates EPO-R expression and elicits downstream signalling in RKC-2 cells. All graphs 
represent mean ± SEM. (A-B) RKC-2 cells were cultured in the presence or absence of 5 U/ml EPO for 24 h. 
(A) EPO-R transcript levels were evaluated by RT-PCR, N = 5–8, *p < 0.05. Rat BMDM (positive control) 
were considered as 1. (B) EPO-R surface expression was evaluated by flow cytometry. Top: Grey and black 
line histograms depict surface EPO-R in control (considered as 1) and EPO-treated cells, respectively. Full 
histogram depicts FITC conjugated Goat anti mouse antibody. Bottom: Quantification of surface EPO-R, 
N = 7, **p < 0.01. (C-D) RKC-2 cells were stimulated for 0, 10 and 30 min with 10 U/ml EPO. Top: Grey, black 
and dashed histograms represent 0, 10 and 30 min EPO-treated cells, respectively. Bottom: The graphs depict 
quantification of mean fluorescence intensity (MFI) of flow cytometry analysis for p-ERK1/2 and p-STAT5, (C) 
and (D), respectively. Levels at 0 min were considered as 1, N = 4–5, **p < 0.01, *p < 0.05.
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as determined by quantitative analysis of the fluorescent fields and flow cytometry, respectively. This was further 
confirmed in sorted KCs, where EPO increased the phagocytosis of microbeads by 2-fold (p < 0.01) (Fig. 2C). 
Similarly, EPO augmented RKC-2 cell phagocytosis of CFSE-labeled heat killed E. coli, as detected by fluorescence 
microscopy (Fig. 2D) and flow cytometry (Fig. 2E), by 340% increase (p < 0.01) and 13% increase (p < 0.01), 
respectively. Our results thus indicate that KCs are direct targets of EPO and that treatment with EPO enhances 
their phagocytic ability.
EPO increases liver KC number and liver EPO-R gene expression. We next investigated in vivo, 
the effect of EPO on liver KCs. Livers from C75BL/6 J mice injected with diluent or EPO (3 injections of 180 U 
EPO on alternating days) were harvested (Fig. 3A). There was an EPO-associated increase in the levels of EPO-R 
mRNA in total liver and a tendency to increased EPO-R mRNA levels in the non-parenchymal cell fraction 
(Fig. 3B). Among these non-parenchymal cells, sorted KCs from EPO-injected mice tended to have higher EPO-R 
gene expression than their counterparts from diluent-injected mice (Fig. 3B). This EPO-associated increase in 
vivo was in line with our findings in the RKC-2 cells (Fig. 1A). Notably, EPO-R expression in Ly6Chi and Ly6Clo 
monocytes (CD45+/CD11bhi/F4/80−/lo/CD64lo/Ly6Chi or Ly6Clo, respectively), which were sorted from untreated 
livers, as well as in BMDM (positive control), was profoundly lower than in KCs (Fig. 3B).
Immunofluorescence staining for the KC-associated macrophage marker F4/80 revealed a 2-fold (p < 0.01) 
increase in the number of KCs following EPO treatment (Fig. 3C). Flow cytometry analysis further confirmed a 
33% increase (p < 0.05) in KC number normalized for tissue mass in the livers of the EPO-treated mice compared 
to diluent-treated mice (Fig. 3D). Of note, the numbers of hepatic lymphocytes, defined as CD45+/CD11b− cells, 
were not affected by EPO administration (Fig. 3D). Similar EPO-governed effects were also observed in Tg6 
mice that are genetically modified to constitutively overexpress EPO in an oxygen-independent manner40, 41. 
Figure 2. EPO increases phagocytosis by KCs. (A) 100,000 RKC-2 cells were cultured for 24 h. On the next 
day, DAPI-labeled RKC-2 cells were incubated ±10 U/ml EPO for 30 min, followed by 30 min incubation with 
fluorescently labeled polystyrene microbeads (green). Rhodamine phalloidin (red) and DAPI (blue) label actin 
and nuclei, respectively. The graph represents quantification of phagocytosed beads (mean ± SEM), N = 6, 
**p < 0.01. Bar = 50 µm. (B) Cells were treated ± EPO as in (A) and analyzed by flow cytometry for uptake 
of fluorescent beads (representative histogram). Grey and black represent control and EPO-treated cells, 
respectively. The graph depicts the fold increase in MFI reflecting the phagocytosis by cells treated with EPO 
compared to saline-treated cells (control, considered as 1). Results are mean ± SEM, N = 5, **p < 0.01. (C) 
100,000 sorted KCs (CD45+/F4/80hi/CD11blo) were treated as described in (A). Phagocytosis by EPO-treated 
cells was normalized to control (considered as 1). Results are mean ± SEM, N = 5, **p < 0.01. (D) 2.5 × 106 
RKC-2 cells were cultured for 24 h. On the next day, DAPI-labeled RKC-2 cells were incubated ±10U/ml EPO 
for 30 min followed by 1 h incubation with 4 × 107 CFSE-labeled E. coli (green). Rhodamine phalloidin (red) 
and DAPI (blue) label actin and nuclei, respectively. The graph represents a quantification of phagocytosed 
CFSE labeled E. coli (mean ± SEM), N = 5, **p < 0.01, Bar = 25 µm. (E) Cells were treated ± EPO as in (D) and 
analyzed by flow cytometry to assay the uptake of CFSE-labeled E. coli (representative histogram). Grey and 
black represent control and EPO-treated cells, respectively. The graph depicts the MFI fold increase reflecting 
the phagocytosis of cells treated with EPO compared to saline-treated cells (control, considered as 1). Results 
are mean ± SEM, N = 6, **p < 0.01.
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Accordingly, we observed an approximately 3-fold increase (p < 0.01) in KC levels in Tg6 mice compared to their 
wild type littermates (Fig. 3E). KCs are normally considered a self-sustaining population that is independent of 
adult BM hematopoiesis39, 42–44. To examine whether the EPO-induced increase in KCs results from local cell pro-
liferation, we analyzed their expression of the Ki67 marker of active proliferation as previously reported39. Flow 
cytometry revealed a 56% increase (p < 0.05) in Ki67+ KCs following EPO administration (Fig. 3F), supporting 
the premise that EPO increases proliferation of KCs in vivo. These findings are in line with the EPO-associated 
increase in liver weight measured in EPO-treated mice compared to diluent-treated mice (10% increase, p < 0.01) 
(Fig. 3G).
We next sought to study whether the EPO-mediated increase in KC number is driven by a direct intrin-
sic cellular mechanism in these cells. An EPO-R-deficiency in the myeloid lineage was obtained by generating 
LysMcre-Eporfl/fl mice. In the liver of these mice, Cre expression driven by the M lysozyme (LysM) promoter mainly 
affects KCs45, though other myeloid cells including macrophages in other tissues are also targeted. While total 
liver cells from LysMcre-Eporfl/fl mice did not exhibit a significant change in Epor gene expression levels compared 
to total liver cells from the relevant controls (Eporfl/fl mice), KCs sorted from these mice displayed a 73% decrease 
(p < 0.01) in Epor transcript levels (Fig. 4A). EPO significantly increased the number of KCs in the control Eporfl/fl 
Figure 3. EPO-treatment increases KC number in vivo. Livers were harvested from C57BL/6 J mice injected 
3 times on alternating days with 180 U EPO or diluent (control). (A) Schematic outline of EPO/diluent 
injections. (B) Left: EPO-R transcript levels in total liver (Liver) and in non-parenchymal cells (NP) from 
diluent and EPO-injected mice. Right: EPO-R transcript levels in sorted KCs (defined as CD45+/CD11bint/
F4/80hi/CD64+ cells39) from diluent (KCs) or EPO-injected mice (KCs + EPO), were evaluated by RT-PCR. 
Graph represents EPO-R transcript levels ± SEM. BMDM served as a positive control27. Ly6Chi = Ly6Chi 
monocytes, Ly6Clo = Ly6Clo monocytes. (C) Frozen sections of the livers were stained with a purified antibody 
directed against F4/80 surface marker followed by Cy3 labeled Goat anti-Rat antibody, and viewed on confocal 
microscopy. Left: Representative analysis of livers from diluent (control) and EPO-injected mice. Right: Bars 
represent mean ± SEM, N = 5–6, **p < 0.01. Bar = 25 µm. (D) Liver non-parenchymal cells were analyzed by 
flow cytometry for CD45, F4/80 and CD11b. Left: Representative analysis of livers from diluent (control) and 
EPO-injected mice. Right: KCs or CD45+/CD11b− (lymphocytes) cell number per gram liver tissue. Graphs 
represent mean ± SEM. For KCs: N = 12-13, *p < 0.05. For CD45+/CD11b− cells: N = 7–8. (E) Livers of EPO-
overexpressing mice (Tg6) or their WT littermates were harvested. Liver non-parenchymal cells were analyzed 
by flow cytometry for CD45, F4/80 and CD11b. Left: Representative analysis of livers from Tg6 versus WT. 
Right: Graphs represent mean ± SEM, N = 6, **p < 0.01 (F) Left: Flow cytometry analysis of Ki67 labelling 
of gated KCs (representative plot). Right: quantification of Ki67 positive KCs, N = 4, *p < 0.05. (G) Graph 
represents liver weight as mean ± SEM, N = 7–9, **p < 0.01.
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mice, but had no effect on KC numbers in the LysMcre-Eporfl/fl mice (Fig. 4B). These results suggest that direct EPO 
signalling can instruct KC proliferation. However, we cannot exclude the possibility that EPO signalling in other 
myeloid cells may also contribute to the increased proliferation of KCs.
EPO increases CCL2-mediated recruitment of Ly6Chi monocytes to the injured liver. Following 
liver injury, liver resident cells including KCs initiate an innate immune response by releasing chemokines such 
as CCL2, which attracts Ly6Chi monocytes39, 46–48. Specifically following challenge with stressed erythrocytes, 
KCs up-regulate CCL2 expression25. EPO treatment induced a 1.5-fold increase (p < 0.01) in serum CCL2 
(Fig. 5A), which was also significantly higher (p < 0.05) in constitutively EPO-overexpressing Tg6 mice com-
pared to their wild type counterparts (Fig. 5B). Cells extracted from total livers of  EPO treated mice displayed 
a 3.7-fold-increase (p < 0.01) in the levels of CCL2 transcripts (Fig. 5C). A breakdown analysis of CCL2 tran-
scripts in the livers of EPO-injected mice revealed a 1.43-fold-increase (p = 0.06) in non-parenchymal cells, and 
a 1.82-fold increase (p < 0.05) in sorted KCs, compared to their control counterparts (Fig. 5C). Moreover, both 
RKC-2 cells and enriched KC cultures (95% positive for F4/80, see Fig. S1) treated with EPO in vitro, showed 
a significant elevation of CCL2 transcripts compared to diluent-treated cells (Fig. 5D). Importantly, while 
LysMcre-Eporfl/fl mice did not display an EPO-driven increase in the levels of serum CCL2 (Fig. 5E) and CCL2 
transcripts in sorted KCs (Fig. 5F), they still exhibited an increase in the levels of CCL2 transcripts in total liver 
cells (Fig. 5F). Thus, EPO may induce CCL2 production by other EPO-R-expressing liver cells, such as hepato-
cytes. Collectively, these findings strongly endorse a central role for EPO in the promotion of KC-governed CCL2 
production.
Egress of Ly6Chi monocytes from the BM to the circulation is known to be mediated by CCR249. As expected 
from its positive effect on CCL2 expression, EPO administration led to an 8-fold (p < 0.05) decrease in the levels 
of CD45+CD11b+CSF1R(CD115)+/Ly6Chi monocytes in the BM (Fig. 5G), while the numbers of their mature 
descendants in the blood were increased by 1.7-fold (p < 0.05) (Fig. 5H). Interestingly, EPO treatment had no 
effect on the expression of other chemokines such as CCL5, CCL8, and CXCL2, although there was a marked 
reduction in the fractalkine chemokine CX3CL1, and an increase in the expression of the neutrophil chemoat-
tractant CXCL1 (Fig. S2). Furthermore, livers from EPO-treated mice exhibited elevated expression of the genes 
encoding for EPO and the anti-inflammatory cytokines IL-10 and TGFβ, with unchanged expression of the 
pro-inflammatory mediators IFNγ and nitric oxide synthase 2 (NOS2) (Fig. S2). To study whether these genes are 
expressed by KCs, we revisited our gene expression database of sorted KCs from steady state livers39. To establish 
the background expression level, their gene expression was compared with that of adiponectin (Adipoq), which 
is uniquely expressed by adipocytes. The gene expression of C-type lectin domain family 4 member F (Clec4f), 
previously defined as a KC specific marker44, was used as a positive control. KCs exhibited clear expression of the 
genes encoding for IL-10, TGFβ1, CCL2, and CXCL1, as well as EPO-R, while they were negative for EPO and 
CX3CL1 (Fig. S2).
We next examined the effect of EPO on the active recruitment of monocytes to the liver in a well-characterized 
murine model of AILI, induced by an overdose of N-acetyl-p-aminophenol (APAP)39. In this model, Ly6Chi 
monocytes massively infiltrate the injured liver during the necro-inflammatory phase (first 24 h) to become the 
dominant mononuclear phagocyte subset in the tissue39. Mice were treated with EPO or saline 24 h before APAP 
administration and then together with the APAP treatment. The impact of EPO treatment on liver infiltration of 
Ly6Chi monocytes was analyzed 24 h after APAP challenge (24 h APAP), as this is the time at which they reach 
maximum accumulation39. Livers were also evaluated 48 h following APAP challenge, when Ly6Chi monocytes 
are still present in the liver and differentiation towards Ly6Clo macrophages is not yet complete39. In this “48 h 
Figure 4. EPO effect on KC levels is abrogated in LysMcre-Eporfl/fl. Eporfl/fl or LysMcre-Eporfl/fl mice were injected 6 
times on alternating days over 2 weeks, with 180 U EPO or diluent (control). (A) EPO-R transcript levels in total 
liver cells and in sorted KCs (CD45+/F4/80hi/CD11blo) from Eporfl/fl mice or LysMcre-Eporfl/fl mice were evaluated 
by RT-PCR. Graph represents EPO-R transcript levels ± SEM, N = 4–6, **p < 0.01. (B) Left: Representative 
analysis of livers from control and EPO-injected Eporfl/fl or LysMcre-Eporfl/fl mice. Right: KC number per liver 
weight (gr). Graphs represent mean ± SEM, N = 4–9, *p < 0.05.
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APAP” group, an additional EPO or saline treatment was administrated 24 h after the APAP injection. CD11b+/
CD11b− cell ratio basically indicates the distribution of phagocytes and lymphoid cells. Treatment with EPO led 
to a 72% and 44% increase (p < 0.01 and p < 0.05, respectively) in phagocyte/lymphoid cell ratio in the liver, at 24 
and 48 h following APAP injection, respectively (Fig. 6A). These results are coupled with the lack of EPO effect 
on the lymphocyte population (Fig. 3D). Treatment with EPO led to a 37% increase (p < 0.05) and 54% increase 
(p < 0.05) in Ly6Chi monocyte levels (defined as CD45+CD11b+Ly6ChiF4/80loCD64loCX3CR1+MHCIIlo) in the 
liver, at 24 and 48 h after APAP injection, respectively (Fig. 6C). Serum levels of CCL2 were similarly high at 24 h 
post APAP, which may be expected given that this is the time of peak induction following AILI39. Notably, EPO 
treatment maintained higher levels of CCL2 [2-fold increase] in the serum at 48 h, when it was already reduced 
in the control group (Fig. 6B).
Figure 5. EPO increases CCL2-deriven egress of Ly6Chi monocytes from BM. (A) Serum CCL2 levels in 
diluent (control) or EPO-injected mice detected by ELISA, graphs represent mean ± SEM, N = 5, **p < 0.01. 
(B) Serum CCL2 levels of EPO-overexpressing mice (Tg6) or their WT littermates detected by ELISA, 
graphs represent mean ± SEM, N = 7–9, *p < 0.05. (C) CCL2 transcript levels in total liver cells (Liver), non-
parenchymal cells (NP) and KCs from diluent (control) or EPO-injected mice, were evaluated by RT-PCR, 
graphs represent mean ± SEM, N = 4–7, **p < 0.01, *p < 0.05. (D) CCL2 transcript levels of RKC-2 cells treated 
with 5 U/ml EPO or diluent (control) in vitro (N = 4) or enriched KCs treated with EPO or diluent (control) in 
vitro (N = 4) were evaluated by RT-PCR, graphs represent mean ± SEM, *p < 0.05. (E) Serum CCL2 levels of 
diluent or EPO-injected Eporfl/flmice or LysMcre-Eporfl/fl mice detected by ELISA, graphs represent mean ± SEM, 
N = 7–13, *p ≤ 0.05. (F) CCL2 transcript levels in total liver cells and in sorted KCs (CD45+/F4/80hi/CD11blo) 
from LysMcre-Eporfl/fl mice were evaluated by RT-PCR. Graph represents CCL2 transcript levels ± SEM, N = 4–6, 
*p < 0.05. (G) BM were analyzed for CD45, CD11b, Ly6G, CD115 and Ly6C by flow cytometry. Left: Gating 
strategy for the definition of monocytes in BM. Right: bar graphs indicate Ly6Chi monocytes as a percentage 
of total BM cells from diluent (control) or EPO-injected mice, N = 7–13, *p < 0.05. (H) Peripheral blood was 
analyzed for CD45, CD11b, Ly6G, CD115 and Ly6C by flow cytometry. Left: Gating strategy for the definition 
of monocytes in blood. Right: bar graphs indicate the number of Ly6Chi monocytes per 50 µl blood from diluent 
(control) or EPO-injected mice, N = 11–12, *p < 0.05.
www.nature.com/scientificreports/
7SCIeNTIFIC REPORTS | 7: 10379  | DOI:10.1038/s41598-017-11082-7
We have recently demonstrated a spatial and temporal overlap in the migration pattern of liver infiltrating 
Ly6Chi monocytes and neutrophils following AILI50. Given the increased expression of the neutrophil chemoat-
tractant CXCL1 in EPO treated livers (Fig. S2), and the observation that KCs express this chemokine (Fig. S2), we 
next followed the effect of EPO treatment on neutrophil recruitment to the injured liver. Indeed, flow cytometry 
analysis revealed a significantly higher infiltration of neutrophils (defined as CD45+CD11b+Ly6CloF4/80-CD64-C
X3CR1-) at 24 h following AILI (Fig. 6C). Moreover, KCs exhibited increased production of CXCL1 transcripts 
in response to direct EPO treatment (Fig. S2), suggesting that KC-EPO axis  may be involved in the attraction of 
neutrophils to the injured liver. Nevertheless, CXCL1 gene expression levels were significantly up-regulated in 
EPO-treated LysMcre-Eporfl/fl mice (Fig. S2), suggesting that EPO-governed signalling in myeloid cells, and in par-
ticular KCs, is not solely responsible for the elevated expression of this neutrophil chemoattractant. Collectively, 
these results support a role for EPO in promoting KC-mediated recruitment of Ly6Chi monocytes and neutrophils 
in response to liver injury.
Discussion
While the main classical role of EPO is considered to be the regulation of red blood cell production, non-erythroid 
effects of EPO have been repeatedly reported7–15. These findings underline the importance of investigating the 
global actions of rHuEPO and its derivatives in pre-clinical and clinical settings. The goal is to maximize benefits, 
while reducing harm. One of the non-erythroid targets of EPO is the immune system. Work with mouse models 
and clinical studies51–53, including our own27, 54–59, have concluded that EPO treatment modulates immunological 
functions. As an example, EPO enhanced BMDM phagocytic activity and nitric oxide secretion in mice, and 
led to augmented IL-12 secretion and decreased IL-10 secretion in response to lipopolysaccharide27. Moreover, 
dendritic cells derived from rat BM responded to EPO stimulation with increased expression of dendritic cell 
activation markers and a higher allostimulatory capacity for T cells51. In chronic renal failure patients, who did 
not require hemodialysis, administration of rHuEPO stimulated rejuvenation of cellular CD8+ T-dependent 
immunity53. Importantly, we29, 54–56, 58, 60 and others61, 62 have linked EPO administration to prolonged survival 
and improved immunological functions in multiple myeloma (MM) mouse models and MM patients. Moreover, 
EPO treatment in hematologic patients improved the response to influenza vaccination63 and normalized the 
levels of impaired CD4+ and CD8+ T cell and CD4+CD25+ cell numbers in low risk myelodysplastic syndrome 
patients (MDS)64.
KCs, the resident tissue macrophages of the liver, play a central role in the pathogenesis and resolution of 
various liver diseases65. We27, 57, 59 and others26 have found functional EPO-R on macrophages derived from BM, 
Figure 6. EPO increases recruitment of Ly6Chi monocytes and neutrophils during AILI. (A) Liver non-
parenchymal cells were analyzed by multi-parameter flow cytometry. The gating strategy for the definition of 
CD11b+ (myeloid cells) or CD11b− (lymphocytes) in the APAP-challenged livers was defined by using CD45, 
F4/80 and CD11b. Bar graphs indicate CD11b+/ CD11b− cell ratio from diluent (control) or EPO-injected mice, 
24 h or 48 h post injection with APAP, N = 5, **p < 0.01, *p < 0.05. (B) Serum CCL2 levels detected by ELISA 
in diluent (control) or EPO-injected mice, 24 h or 48 h after treatment with APAP, N = 4–10, *p ≤ 0.05. (C) 
Liver non-parenchymal cells were analyzed by flow cytometry. The gating strategy for the definition of Ly6Chi 
monocytes or neutrophils in the APAP-challenged liver was defined by using CD45, F4/80, CD11b, Ly6C, 
CX3CR1 and MHCII. Bar graphs indicate Ly6Chi monocytes or neutrophils as a percent of CD45+ liver cells 
from diluent (control) or EPO-injected mice, 24 h or 48 h post injection with APAP, N = 4–10, *p < 0.05. All 
graphs represent mean ± SEM.
www.nature.com/scientificreports/
8SCIeNTIFIC REPORTS | 7: 10379  | DOI:10.1038/s41598-017-11082-7
peritoneum and spleen. By data mining in a gene expression database of steady state KCs39, we show here that 
these cells express EPO-R at the gene level. This has previously been shown for rat KCs66. Nevertheless, it was 
not yet clear whether this receptor is functional and the nature of the effect of EPO on KC immunity remained 
elusive. Here we demonstrate for the first time that KCs express a functional EPO-R, which activates down-
stream signalling in response to EPO, to regulate KC number and function. We also show that EPO promotes 
KC-mediated Ly6Chi monocyte and neutrophil recruitment to the challenged liver via production of CCL2 and 
CXCL1, respectively.
Being strategically positioned in the liver, KCs are characteristically involved in the phagocytosis of debris, 
pathogens, and apoptotic, damaged or senescent cells (including erythrocytes)67–69. They display high phagocytic 
and lysosomal activities, which relate to their specialization in filtering blood that enters the sinusoids. Thus, they 
are considered to play a key role in immune surveillance, iron metabolism, and detoxification in the liver. Our 
results demonstrate that treatment with EPO elicits EPO-R downstream signalling in cultured KCs and increases 
the capacity of cultured and sorted primary KCs to phagocytose. Therefore, EPO may directly license the ability of 
KCs to reduce any excess of red blood cells in the liver after its administration. This is also in line with a previous 
report indicating that peritoneal macrophages from EPO-treated mice, display enhanced apoptotic cell clearance 
through the peroxisome proliferator activated receptor-γ (PPARγ)26, 37, 38 as well as increased removal of debris37.
Under homeostatic conditions, KCs are replenished by a self-renewal process that is independent of adult BM 
hematopoiesis39, 42–44. Our results indicate that the increase in KCs following EPO administration in vivo is medi-
ated, at least in part, by their local proliferation. Emerging evidence indicates that macrophage niche availability 
restricts tissue resident macrophage self-maintenance capacity70. The expansion in liver tissue mass following 
EPO treatment that we report here, may be accompanied by the inauguration of new macrophage niches that 
are then available for the arrival of de-novo KCs generated by self-proliferation of the already existing resident 
KC population. This is supported by our observation that the EPO-driven increase in KC levels is abrogated in 
LysMcreEporfl/fl mice, where EPO-R-deficiency is targeted to myeloid cells. KCs are the main myeloid resident 
cell population in the normal liver45, and they exhibit a 73% reduction in EPO-R expression in the LysMcreEporfl/
fl mice. These results thus suggest that EPO can directly instruct KC proliferation; although we cannot exclude 
an alternative possibility that EPO indirectly affects KC expansion. Under certain circumstances in which res-
ident macrophage niches are open, circulating Ly6Chi monocytes can also differentiate into self-maintaining 
tissue-resident macrophages that resemble their embryonic counterparts70. Indeed, in cases when the KC pool is 
diminished such as following lethal irradiation or diphtheria toxin induced ablation44, or more physiologically, 
following Listeria monocytogenes-induced KC necroptosis71, Ly6Chi monocytes are capable of reconstituting the 
KC compartment. Our results, demonstrating that EPO mediates the egress of Ly6Chi monocytes from the BM to 
the circulation, suggest that these cells may also contribute to the expansion of KC population.
Prolonged EPO administration, as is often prescribed in clinical conditions such as anemia, may pose a chal-
lenge to the liver. Our results suggest that in such a scenario, activation of the EPO/EPO-R axis in KCs induces 
their proliferation and phagocytic activity, and thus licenses them to clear damaged and stressed red blood cells. 
Further substantiating this argument, are the results showing that EPO stimulates CCL2 production in KCs, and 
promotes the egress of Ly6Chi monocytes from the BM to the circulation. It has been recently shown in a mouse 
model of hemolytic anemia, that CCL2-dependent Ly6Chi monocyte recruitment to the liver is important for the 
clearance of senescent and dying erythrocytes, and protection from iron toxicity25. Therefore, EPO-mediated 
up-regulation of CCL2 production by KCs may be an additional pathway participating in the clearance of excess 
erythrocytes in the liver.
The EPO mediated in vivo increase in serum and liver CCL2 (protein and transcripts, respectively), and the 
absence of this EPO-driven phenotype in KCs isolated from LysMcre-Eporfl/fl mice, strongly suggest that acti-
vation of EPO-R in KCs contributes to this EPO mediated response. It should be noted that in LysMcre mice, 
Cre-mediated deletion, specificity and efficiency is mainly restricted to macrophages, monocytes and neutro-
phils with little effect on other immune cells such as T cells, B cells, NK cells, eosinophils, dendritic cells, and 
mast cells72. Indeed, the depletion of EPO-R in the KC compartment, but not in total liver preparations from 
LysMcre-Eporfl/fl mice, indicates that EPO-R is mainly restricted to KCs. In addition, we show that monocytes have 
significantly less EPO-R than KCs and although we could not directly examine the expression of a functional 
EPO-R in sorted neutrophils due to their poor viability following isolation, a previous study has indicated that 
extended EPO administration has no effect on neutrophil pools in vivo73. Moreover, neutrophils were profoundly 
outnumbered by KCs in the liver following EPO treatment (Data not shown). We provide a direct evidence for the 
existence of an EPO-KCs-CCL2 axis. First, EPO treatment stimulated CCL2 production in a Kupffer cell line as 
well as in enriched cultured primary KCs. Second; the EPO-mediated increase in CCL2 transcripts was abrogated 
in KCs sorted from LysMcre-Eporfl/fl mice and not in KCs from the control mice. Nevertheless, we cannot negate 
the participation of other cells in the liver that can produce monocyte and neutrophil attracting chemokines. 
This is especially true for hepatocytes, which are a prominent source for specific chemokines such as CCL2 under 
various challenging conditions74. As hepatocytes also express a functional EPO-R66, 75 they may contribute to 
the EPO driven increase in total liver CCL2 transcripts and serum CCL2. In support of this, we show that the 
EPO driven increase in CCL2 gene expression is maintained in the livers of LysMcre-Eporfl/fl mice, whose KCs 
lack EPO-R expression. Therefore, EPO may favor hepatocyte-mediated recruitment of Ly6Chi monocytes to the 
challenged liver.
We show that EPO transcripts are elevated in the liver following systemic EPO treatment, although the mech-
anism of action and the nature of the cells that mediate this response remain elusive. Notably, extra-renal EPO 
production has been demonstrated in resident liver cells including hepatocytes and perisinusoidal Ito cells44, and 
was shown to increase following an acute-phase response in a rat model46. Local elevation in EPO levels has been 
documented in various liver pathologies, including AILI, and iron loading may perpetuate hepatic damage and 
compromise healing76, 77. Moreover, EPO has been suggested to play a protective role in the resolution of liver 
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injury16–18. Hepatic infiltration of Ly6Chi monocytes was reported in various acute or chronic liver injuries39, 78–81 
and we have previously shown that Ly6Chi monocytes in the liver give rise to pro-restorative ephemeral mac-
rophages during AILI39. This is in accordance with our results here showing that the administration of EPO in 
an acute model of AILI maintains high levels of CCL2 in the serum and promotes the downstream recruitment 
of Ly6Chi monocytes to the liver. Since KCs are also pivotal players in the recovery from AILI82, the role of EPO 
in liver resolution may therefore be through stimulation of KC proliferation, phagocytosis and recruitment of 
Ly6Chi monocytes. Interestingly, neutrophil recruitment to the injured liver was also significantly augmented 
by EPO treatment at 24 h following APAP. The CXCL1 neutrophil chemoattractant was elevated in response to 
a week of EPO treatment in steady state mice. Notably, we show that KCs express elevated CXCL1 transcripts in 
response to EPO, raising the possibility that these cells also drive neutrophil mobilization in response to EPO. 
However, the observation that EPO also increased the levels of CXCL1 transcripts in the liver of LysMcre-Eporfl/
fl mice, suggests that EPO-responsive cells other than KCs may produce CXCL1. Hepatocytes have been shown 
to express a functional EPO-R66, 75 and these cells may be candidates to mobilize neutrophils from the BM via 
their release of CXCL183. In conclusion, we report a novel function of EPO associated with the regulation of KC 
number and function in the liver.
Materials and Methods
Mice. Female C57BL/6J-OlaHsd mice (8–12-weeks old) were purchased from Envigo Laboratories (Israel, 
formerly Harlan Laboratories). Mice were injected subcutaneously (s.c.) three times (every other day during 1 
week) with 180 U rHuEPO (EPO, Epoetin α, Eprex®, Janssen), with diluent (saline) as previously described27, 
or as otherwise indicated. Mouse handling and the experimental procedures were approved by the Institutional 
Animal Care and Use Committee of the Tel-Aviv University (permit number: M-15-046), or Sourasky Medical 
Center Animal facility (5-6-16). All the experiments were conducted in accordance with the approved guidelines.
C57BL/6 J mice at the age of 9–11 weeks, as well as Eporfl/fl and LysMcre-Eporfl/fl mice, were injected subcutane-
ously (s.c.) six times (every other day for 2 weeks) with 180 U rHuEPO or with diluent (saline). Mouse handling 
and the experimental procedures were approved by the Institutional Animal Care and Use Committee of the 
Tel-Aviv University (permit number: M-14-093) in accordance with the approved guidelines.
Rat RKC-2 - Cell line. The immortalized rat Kupffer cell line 2, RKC-230 was kindly provided by Prof. T. 
Hunter (USF, University of South Florida). Cells were maintained in RPMI 1640 medium supplemented with 10% 
FCS at 37 °C and 5% CO2. For experiments, RKC-2 cells were cultured for 24 h or as otherwise indicated, in RPMI 
1640, containing EPO as indicated below.
Kupffer cells enrichment ex vivo. KCs were separated from hepatocytes and other sinusoidal cells by 
gradient centrifugation. Specifically, mice were perfused with 30 ml of cold PBS and the liver was excised. Livers 
were cut into small fragments, incubated with mixing (37 °C, 250 rpm for 45 min) with 5 ml digestion buffer [5% 
FCS, 0.5 mg/ml collagenase IV (Sigma-Aldrich, Rehovot, Israel, C5138-500MG) in PBS] and filtered through 
200 μM wire mesh. Cells were suspended in 5 ml RPMI 1640 and centrifuged at 300 g for 5 min at 4 °C, then the 
top aqueous phase was discarded. The cell sediments were resuspended in 10 ml RPMI 1640 and centrifuged at 
50 g for 3 min at 4 °C. The top aqueous phase (cleared cell suspension) was transferred into a new 10 ml centrifuge 
tube and centrifuged at 300 g for 5 min at 4 °C, then the top aqueous phase was discarded, and the cell sediments 
were reserved. The cell sediments mainly contained non-parenchymal cells of the liver including KCs, sinusoidal 
endothelial cells, and satellite cells. Selective adherence to plastic as described by Blomhoff et al.84 was used to 
purify this cell population further. The cells were then seeded into 10 cm plates in DMEM containing 10% FBS, 
1% L-Glutamine (L-Glu) and 0.1% Penicillin Streptomycin (PS), and incubated for 1 h in a 5% CO2 atmosphere 
at 37 °C. Non-adherent cells were then removed from the dish by gently washing with PBS, to leave the adherent 
KCs. Cells were grown for 7–10 days in culture until they displayed morphologic features typical of macrophages.
Erythropoietin (EPO). GMP-manufactured sterile syringes containing rHuEPO (Epoetin alfa, Eprex®) as 
used for patient care, were kindly provided by Janssen Cilag, Israel, and employed throughout this study, thus 
ensuring the absence of toxins in the rHuEPO preparation.
APAP administration. Mice were fasted overnight for 12 h prior to administration of diluent (saline) or 
300 mg/kg APAP (CAT# 7085, SIGMA) by intraperitoneal injection (i.p). Drinking water was provided at the 
same time as APAP administration and access to food was restored 2 h later.
Surface EPO-R expression. Rat RKC-2 cells (1 × 105 cells) were incubated in 6-well plates and stimu-
lated in the presence or absence of EPO 5 U/ml. After 24 h, the cells were collected and labeled with anti EPO-R 
antibody (GM1202, Aldevron, Freiburg31), followed by FITC conjugated Goat anti mouse antibody (Jackson 
ImmunoResearch, CAT#115-0095-003). The stained cells were examined by GalliosTM Flow cytometer and ana-
lyzed using Kaluza Analysis Software (Beckman Coulter, Nyon Switzerland).
PhosphoFlow of RKC-2 cell line. RKC-2 cells were starved for 1 h and aliquoted to Eppendorf tubes (106 
cells/ 90 µl RPMI 1640). They were then incubated (37 °C, 5 min) followed by activation with 10 U/ml EPO for 0, 
10, and 30 min. The reaction was stopped with 10 µL of 37% formalin, giving a final concentration of 3.7% for-
malin. Cells were incubated for 1 min at 37 °C, and then cooled on ice for 5 min and centrifuged (3,000 rpm for 
2 min). After this, the cells were washed once with 1% BSA/PBS and centrifuged (3,000 rpm for 2 min). Staining 
for the intracellular proteins [(PE eFluor 610 pSTAT5 (eBioscience 61-9010-42) and p-ERK (sc-7383) followed 
by an FITC conjugated Goat anti-mouse antibody] was done in Saponin (Invitrogen) 1%BSA/PBS. The cells were 
incubated for 1 h in the dark at room temperature and then centrifuged and resuspended in Flow buffer. The 
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stained cells were examined by GalliosTM Flow cytometer and analyzed using Kaluza Analysis Software (Beckman 
Coulter, Nyon Switzerland).
Macrophage phagocytosis of fluorescently labelled E. coli or fluorescently labelled 
beads. 2 × 105 RKC-2 cells were seeded in 60 mm plates overnight at 37 °C to allow cell adhesion. The next 
day, E. coli (strain BL21) were heat killed by incubation at 65 °C for 1 h and washed twice with PBS. They were 
then labelled with CFSE [M CFDA (Molecular Probes)] for 15 min at room temperature and washed thoroughly 
in PBS. RKC-2 cells were incubated ±10 U/ml EPO followed by stimulation with CFSE-labeled E coli (40 mil-
lion cells) or fluorescently labeled beads diluted 1:800 (Fluoresbrite TM Plain YG 1.0 Micron Microspheres, 
CAT#17154, Polysciences Inc) for the indicated concentrations and time points. Free bacteria that had not been 
phagocytosed by RKC-2 cells were washed away. Cells were aliquoted to FACS tubes and analyzed on a GalliosTM 
Flow Cytometer (Beckman Coulter). Similarly, 1 × 105 sorted KCs (CD45+/F4/80hi/CD11blo) were cultured in 
6-well plates for 24 h. On the next day, the cells were incubated ±10 U/ml EPO for 30 min, followed by 30 min 
incubation with fluorescently labeled polystyrene microbeads. Cells were analyzed by flow cytometry for uptake 
of fluorescent beads.
Immunofluorescence assay. RKC-2 cells (105 cells in 500 µl per well in 24 well plates) were treated with 
EPO and E. coli or beads (as described above) then washed three times with PBS and fixed in 4% paraformalde-
hyde diluted in PBS for 30 min at room temperature. The cells were then washed three times with PBS, perforated 
by incubation in quenching buffer (0.1% Triton × 100, 2% BSA, 5% FBS in PBS) for 15 min at room temperature, 
and stained with Rhodamine-phalloidin according to manufacturer’s instructions (Molecular Probes). Cells were 
mounted on slides using Fluorescent Mounting Medium with DAPI (GBI Labs, WA, USA) and were visualized 
using a Leica SP5 microscope, (Buffalo Grove, IL, NA), lens × 63. Images were captured and analyzed using LAS 
LF lite software.
Isolation of hepatic non- parenchymal cells for flow cytometry and sorting. Mice were perfused 
with 30 ml of cold PBS and the liver was excised. Livers were cut into small fragments, incubated (37 °C, 250 rpm 
for 45 min) with 5 ml digestion buffer [5% FCS, 0.5 mg/ml collagenase IV (Sigma-Aldrich, Rehovot, Israel, C5138-
500MG) in PBS] and filtered through 200 μM wire mesh. This was followed by three cycles of washings with PBS 
at 400 rpm, 4 °C, 5 min, harvesting the supernatant and discarding the parenchymal cell pellet. The supernatant 
was centrifuged at 1500 rpm, 4 °C, 5 min and the erythrocytes in the cell pellet were lysed by a 2 min incubation 
with ACK Lysing buffer (Quality Biological, CAT# 118-156-721).
Flow cytometry analysis and sorting of macrophages, monocytes and neutrophils. The follow-
ing fluorescence-conjugated antibodies were used for KC characterization: APC Cy7 CD45 (BioLegend 103116), 
APC CD64 (BioLegend 139306), PE Cy7 CD11b (BioLegend, 101216), PE F4/80 (serotec, MCA497), FITC KI-67 
(eBioscience 11-5698-80), Purified CD16/32 (BioLegend 101302), and the relevant isotype controls. KCs were 
defined as CD45+/CD11bint/F4/80hi/CD64+ cells39.
Antibodies used for liver monocyte and neutrophil characterization included: APC Cy7 CD45 (BioLegend 
103116), PE F4/80 (serotec, MCA497), PE-Cy7 CD11b (BioLegend, 101216), PerCP Cy 5.5 LY6C (BioLegend, 
128012), Pacific blue MHC class II (I-Ab, BioLegend 107620), Alexa Fluor® 488 CX3CR1 (BLG-149021), Purified 
CD16/32 (BioLegend, 101302) and the relevant isotype controls.
Antibodies used for BM and blood monocyte characterization included: APC Cy7 CD45 (BioLegend 103116), 
PE-Cy7 CD11b (BioLegend, 101216), Brilliant Violet 421 LY6G (BioLegend, 127627), APC CD115 (eBioscience 
17-1152-82), PerCP Cy 5.5 LY6C (BioLegend, 128012), purified CD16/32 (BioLegend, 101302) and the relevant 
isotype controls.
Cells were analyzed on a GalliosTM Flow Cytometer (Beckman Coulter) and sorted on a BD FACSAria Cell 
Sorter (BS Biosciences). Flow cytometry analysis was performed using Kaluza Analysis Software.
Immunofluorescence of frozen tissue sections. Liver samples obtained from EPO or diluent-injected 
mice were frozen at −80 °C, sectioned, and stained for F4/80 (eBioscience, 14-4801-81) followed by a Cy3 conju-
gated Goat anti Rat (Jackson ImmunoResearch, CAT#112-165-167).
Real-time quantitative PCR. Total RNA from murine liver tissue or from rat RKC-2 cells was extracted and 
dissolved in TRIzol Reagent (Invitrogen, Grand Island, NY, USA) according to the manufacturer’s instruction, and 
from sorted KCs with the GENEzol TriRNA Pure Kit (Geneaid, New Taipei City, Taiwan) according to the manu-
facturer’s protocol. cDNA was prepared using a high capacity cDNA reverse transcription kit (Applied Biosystems, 
California, USA). Real-time quantitative PCR was performed using the StepOnePlus Real-time PCR system 
and the KAPA SYBR FAST ABI Prism qPCR Kit (Kapabiosystems). HPRT (mouse) or TBP (rat) housekeeping 
genes were used as an internal standardization control. Primer sequences used for amplification were as follows: 
Rat EPO-R, 5′-CCACATCCGCTACGAGGT-3′ (forward) and 5′-GCCTTCCAGGACCTCCAC-3′ (reverse); 
Rat TBP, 5′-CCCACCAGCAGTTCAGTAGC-3′ (forward) and 5′-CAATTCTGGGTTTGATCATTCTG-3′ 
(reverse); Mouse EPO-R, 5′-GTCCTCATCTCGCTGTTGCT-3′ (forward) and 5′-ATGCCAGGCAGA 
TCTTCT-3′ (reverse); Mouse MCP-1/CCL-2, 5′-TCTCTCTTCCTCCACCAC-3′ (forward) and 5′-GTGGGGCGTT 
AACTGCAT-3′ (reverse); Mouse CXCL2, 5′-AGTGAACTGCGCTGTCAATG-3′ (forward) and 5′-TTCAGGGTC 
AAGGCAAACTT-3′ (reverse); Mouse CXCL1 5′–CTTGAAGGTGTTGCCCTCAG-3′ (forward) and 
5′-TCTGAACCAAGGGAGCTTCA-3′ (reverse);, Mouse CCL8, 5′-TAAGGCTCCAGTCACCTGCT-3′ (for-
ward) and 5′-ATACCCTGCTTGGTCTGGAA-3′ (reverse); Mouse CCL5 5′-CTGCTGCTTTGCCTACCTCT-3′ 
(forward) and 5′-CCCACTTCTTCTCTGGGTTG-3′ (reverse); Mouse IFNγ, 5′-TCAAAAGAGTTCCTTATG-3′ 
(forward) and 5′-TACGAGGACGGAGAGCTG- 3′ (reverse); Mouse NOS2, 5′-ACCTTGTTCAGCTACGCC-3′ 
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(forward) and 5′- CATTCCCAAATGTGCTTG- 3′ (reverse); Mouse IL-10, 5′-CAGAGCCACATGCTCCTA-3′ 
(forward) and 5′-GTCCAGCTGGTCCTTTGT-3′ (reverse); Mouse TGFβ, 5′-TGGAGCAACATGTGGAAC’−3′ 
(forward) and 5′-CAGCAGCCGGTTACCAAG-3′ (reverse), Mouse CX3CL1, 5′-CATGTGCGAC 
AAGATGACCT-3′ (forward) and 5′-CAGAAGCGTCTGTGCTGTGT-3′  (reverse); Mouse HPRT, 
5′-TCCTCCTCAGACCGCTTTT-3′ (forward) and 5′-CCTGGTTCATCATCGCTAATC-3′ (reverse); Mouse 
RPLPO, 5′-CAACCCAGCTCTGGAGAAAC-3′ (forward) and 5′-GTTCTGAGCTGGCACAGTGA-3′ (reverse).
ELISA assay. Blood from treated or untreated mice was incubated for 2 h at 25 °C and centrifuged at 
6,000 rpm, 25 °C for 30 min. Serum was collected and diluted 1:2 (for EPO or diluent-injected mice) or 1:10 (for 
Tg6-EPO overexpressing mice or wild type mice) in 96 well-plates. CCL2 protein levels were assayed by an ELISA 
kit (CAT #MJE00, R&D systems), according to the manufacturer’s instructions. Plates were read at 450 nm in an 
ELISA reader (SpectraMAX 190 microplate reader).
Statistical analysis. Values are presented as mean ± SEM unless otherwise indicated; The non parametric 
Mann-Whitney U test was used for comparison. A significant difference between groups was defined as p < 0.05. 
All data generated or analyzed during this study are included in this published article.
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